Directors' Interest in Shares

Oxford Biomedica PLC
13 March 2008


For Immediate Release                                              13 March 2008



                      Oxford BioMedica plc ('the Company')


                Directors' Interest in Shares and Share Options


Oxford BioMedica (OXB:L) The Company today announced that on 13 March 2008 the
following awards under the Oxford BioMedica plc Long Term Incentive Plan (LTIP)
were made to six executive directors.


                                       LTIP:    Total shares    Percentage of
                                     number of  over which      issued shares
                                      shares    options are     under option
                                      awarded   held (note 1)

Alan Kingsman                         1,291,871    2,605,404         0.49%
Susan Kingsman                          565,640    1,643,331         0.31%
Michael McDonald                      1,017,542    3,087,843         0.57%
Andrew Wood                             977,533    2,384,974         0.44%
Peter Nolan                             771,400    1,612,355         0.30%
Nick Woolf                              788,582    2,434,867         0.45%


Note 1: The total shares over which options are held (share options granted
between April 2001 and September 2006 and LTIPs awarded since March 2007)
following the awards described above.


The share price on which the awards were calculated was 22.5p (the closing price
on the day preceding the awards). The LTIP awards are nil-cost options. The LTIP
awards are subject to a three year holding period, and are exercisable on the
third anniversary of the award, subject to the satisfaction of a Total
Shareholder Return (TSR) performance condition described below.


No awards will be released at the testing date for less than median performance
of Oxford BioMedica TSR compared to a comparator group made up of 20 companies
from the biotechnology and healthcare sectors. Median performance will result in
release of 25% of the shares. Upper quartile performance (i.e. greater than 75th
percentile performance) will result in release of 100% of the shares, with
straight line release between these points. If the performance conditions are
not satisfied or partially satisfied at the end of the holding period, the LTIP
award or the balance of the award (as appropriate) not released shall lapse.
There will be no re-testing of the performance conditions.



Andrew Wood

Company Secretary, Oxford BioMedica plc

13 March 2008



                      This information is provided by RNS
            The company news service from the London Stock Exchange